L'hôpital d'instruction des armées Bégin est un hôpital militaire situé au 69, avenue de Paris à Saint-Mandé dans le Val-de-Marne, près de Paris. Il porte le nom de Louis Jacques Bégin, chirurgien militaire de l'Empire.

During the past decade, HIA Begin conducted 64 clinical trials. In the 10-year time frame, 64 clinical trials started and 9 clinical trials were completed, i.e. on average, 14.1% percent of trials that started reached the finish line to date. In the past 5 years, 35 clinical trials started and 9 clinical trials were completed. i.e. 25.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "HIA Begin" #1 sponsor was "Direction Centrale du Service de Santé des Armées" with 9 trials, followed by "Hoffmann-La Roche" with 9 trials sponsored, "Janssen Research & Development, LLC" with 8 trials sponsored, "Federation Francophone de Cancerologie Digestive" with 5 trials sponsored and "UNICANCER" with 5 trials sponsored. Other sponsors include 31 different institutions and companies that sponsored additional 31 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "HIA Begin" #1 collaborator was "AstraZeneca" with 4 trials as a collaborator, "Daiichi Sankyo Co., Ltd." with 3 trials as a collaborator, "National Cancer Institute, France" with 2 trials as a collaborator, "ARCAGY/ GINECO GROUP" with 1 trials as a collaborator and "Association de Neuro-Oncologues d'Expression Francaise" with 1 trials as a collaborator. Other collaborators include 10 different institutions and companies that were collaborators in the rest 20 trials.

According to Clinical.Site data, the most researched conditions in "HIA Begin" are "Prostate Cancer" (5 trials), "Breast Cancer" (3 trials), "Cancer" (3 trials), "Carcinoma, Non-Small-Cell Lung" (3 trials) and "Castration-Resistant Prostatic Cancer" (2 trials). Many other conditions were trialed in "HIA Begin" in a lesser frequency.

Most popular intervention types in "HIA Begin" are "Drug" (45 trials), "Other" (13 trials), "Biological" (7 trials), "Procedure" (5 trials) and "Radiation" (5 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (10 trials), "Pemetrexed" (9 trials), "Carboplatin" (8 trials), "Cisplatin" (6 trials) and "Atezolizumab" (5 trials). Other intervention names were less common.

The vast majority of trials in "HIA Begin" are 55 trials for "All" genders, 16 trials for "Male" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "HIA Begin". 1 are not yet recruiting, 25 are recruiting, 18 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 22 completed trials in HIA Begin, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in HIA Begin, 6 "Phase 1" clinical trials were conducted, 9 "Phase 2" clinical trials and 36 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 6 trials that are defined as “Not Applicable".